Cytomegalovirus - problems due to congenital infection

被引:0
作者
Dunal, Milena [1 ]
Trzcinska, Agnieszka [1 ]
Siennicka, Joanna [1 ]
机构
[1] Panstwowy Zaklad Higieny, Narodowy Inst Zdrowia Publicznego, Zaklad Wirusol, PL-00791 Warsaw, Poland
来源
POSTEPY MIKROBIOLOGII | 2013年 / 52卷 / 01期
关键词
CMV; congenital infection; prevention; diagnosis; treatment; TIME PCR QUANTIFICATION; AMNIOTIC-FLUID; BREAST-MILK; DAY-CARE; INTRAUTERINE TRANSMISSION; GANCICLOVIR THERAPY; PRENATAL-DIAGNOSIS; ANTIVIRAL THERAPY; PREGNANT-WOMEN; PREVENTION;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human cytomegalovirus (CMV) is the most common cause of perinatal viral infections in the developed world and the leading cause of congenital infections. About 30-40% infected pregnant women transmit the infection to their fetus. The consequences of CMV infection on pregnant women are very diverse, however, due to their universality, are a serious public health problem. Therefore, the development of prevention in the form of an effective vaccine is one of the priorities of the World Health Organization. Until the vaccine is implemented, it seems very important to raise awareness about the risks associated with CMV infection. The epidemiology, clinical manifestations, prevention, diagnosis and treatment of CMV congenital infection are reviewed. 1. Introduction. 2. The structure of cytomegalovirus. 3. CMV replication. 4. Latency. 5. Pathogenesis and clinical forms of infection. 6. Epidemiology. 7. Congenital CMV infection. 8. Diagnosis of congenital infection. 8.1. Serological tests for mothers. 8.2. Examination of amniotic fluid. 8.3. USG. 8.4. Diagnosis of congenital infection in a newborn. 9. Prevention and treatment. 9.1. The vaccine. 9.2. Passive immunization. 9.3. Antivirals. 9.4. Prevention of CMV infection. 10. Summary
引用
收藏
页码:17 / 28
页数:12
相关论文
共 99 条
[1]  
Adler S P, 1992, Adv Pediatr Infect Dis, V7, P109
[2]   CYTOMEGALOVIRUS AND CHILD DAY-CARE - RISK-FACTORS FOR MATERNAL INFECTION [J].
ADLER, SP .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (08) :590-594
[3]   Safety and immunogenicity of the Towne strain cytomegalovirus vaccine [J].
Adler, SP ;
Hempfling, SH ;
Starr, SE ;
Plotkin, SA ;
Riddell, S .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (03) :200-206
[4]   Prevention of child-to-mother transmission of cytomegalovirus among pregnant women [J].
Adler, SP ;
Finney, JW ;
Manganello, AM ;
Best, AM .
JOURNAL OF PEDIATRICS, 2004, 145 (04) :485-491
[5]   MOLECULAR EPIDEMIOLOGY OF CYTOMEGALOVIRUS - A STUDY OF FACTORS AFFECTING TRANSMISSION AMONG CHILDREN AT 3 DAY-CARE-CENTERS [J].
ADLER, SP .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (08) :584-590
[6]  
Adler Stuart P, 2011, Infect Dis Obstet Gynecol, V2011, P1, DOI 10.1155/2011/942937
[7]   Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus [J].
Arcenas, Rodney C. ;
Widen, Raymond .
BMC MICROBIOLOGY, 2002, 2 (1) :1-13
[8]   Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee [J].
Arvin, AM ;
Fast, P ;
Myers, M ;
Plotkin, S ;
Rabinovich, R .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (02) :233-239
[9]  
Bodéus M, 1999, PRENATAL DIAG, V19, P314, DOI 10.1002/(SICI)1097-0223(199904)19:4<314::AID-PD542>3.0.CO
[10]  
2-H